Pharmaceuticals company Hester Biosciences announced Q3FY26 results Revenue: Rs 774.15 million against Rs 632.18 million during Q3FY25, change 22%. EBITDA: Rs 197.77 million against Rs 138.45 million during Q3FY25, change 43%. EBITDA Margin: 26% for Q3FY26. PAT: Rs 93.1 million against Rs 114.08 million during Q3FY25, change -18%. PAT Margin: 12% for Q3FY26. EPS: 10.94 for Q3FY26. The Poultry Healthcare Division delivered 32% growth in Q3 FY26 and 17% growth in 9M FY26, driven by deeper market penetration, improved placements and sustained demand for our vaccines. The Animal Healthcare Division recorded a 38% decline in Q3 FY26 and a 40% decline in 9M FY26, primarily due to delays in government-led immunisation programmes in the ruminant segment, particularly PPR and Goat Pox (for immunising against the Lumpy Skin Disease). Result PDF